1 Capturing intrahost recombination of SARS-CoV-2 during superinfection with Alpha and 2 Epsilon variants in New York City

- 3
- 4 Authors: Joel O. Wertheim^{1,*}, Jade C. Wang^{2,*}, Mindy Leelawong², Darren P. Martin³, Jennifer
- 5 L. Havens⁴, Moinuddin A. Chowdhury², Jonathan Pekar⁴, Helly Amin², Anthony Arroyo², Gordon
- 6 A. Awandare⁵, Hoi Yan Chow², Edimarlyn Gonzalez², Elizabeth Luoma⁶, Collins M. Morang'a⁵,
- 7 Anton Nekrutenko⁷, Stephen D. Shank⁸, Peter K. Quashie⁵, Jennifer L. Rakeman², Victoria
- 8 Ruiz², Lucia V. Torian², Tetyana I. Vasylyeva¹, Sergei L. Kosakovsky Pond⁸, and Scott Hughes²
- 9
- ¹ Department of Medicine, University of California San Diego, La Jolla, CA, USA
- ² New York City Public Health Laboratory, New York City Department of Health and Mental
- 12 Hygiene, New York, NY, USA
- ³ Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town,
 South Africa
- 14 South Africa
- ⁴ Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La
 Jolla, CA, US
- ⁵West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana,
- 18 Accra, Ghana
- ⁶ Bureau of the Communicable Diseases, New York City Department of Health and Mental
- 20 Hygiene, Long Island City, NY, USA
- ⁷ Department of Biochemistry and Molecular Biology, The Pennsylvania State University, State
- 22 College, PA, USA
- ⁸ Department of Biology, Temple University, Philadelphia, PA USA
- 24

26

- 25 *These authors contributed equally to this work
- 27 To whom correspondence should be addressed: jwertheim@health.ucsd.edu;
- 28 jwang7@health.nyc.gov
- 29

30 ABSTRACT

31

32 Recombination is an evolutionary process by which many pathogens generate diversity and

33 acquire novel functions. Although a common occurrence during coronavirus replication,

34 recombination can only be detected when two genetically distinct viruses contemporaneously

35 infect the same host. Here, we identify an instance of SARS-CoV-2 superinfection, whereby an

36 individual was simultaneously infected with two distinct viral variants: Alpha (B.1.1.7) and

37 Epsilon (B.1.429). This superinfection was first noted when an Alpha genome sequence failed to

38 exhibit the classic S gene target failure behavior used to track this variant. Full genome

39 sequencing from four independent extracts revealed that Alpha variant alleles comprised

40 between 70-80% of the genomes, whereas the Epsilon variant alleles comprised between 20-

41 30% of the sample. Further investigation revealed the presence of numerous recombinant

42 haplotypes spanning the genome, specifically in the spike, nucleocapsid, and ORF 8 coding

43 regions. These findings support the potential for recombination to reshape SARS-CoV-2 genetic

44 diversity.

45 INTRODUCTION

46

47 Recombination is a common evolutionary feature of positive-strand RNA viruses¹. It can

48 increase genetic diversity and accelerate adaptation in viral populations by combining existing

49 linked allelic variation. The signature of frequent recombination is pervasive across

50 Betacoronaviruses in bats and other animal ²⁻⁶ hosts, and its detection is made easier in part by

51 the substantial genetic divergence separating these various coronaviruses. When an individual

52 is simultaneously infected with two genetically distinct strains of a virus, so-called superinfection

⁷, these viruses can recombine to produce a virus with novel allelic combinations. Although

54 recombination is expected to regularly occur during SARS-CoV-2 infections, it can be difficult to

detect *in vivo* unless it involves genetically distinguishable parental strains: recombination
 between two identical or nearly identical genomes leaves no detectable molecular trace.

57 Furthermore, as with influenza virus ^{8,9}, SARS-CoV-2 superinfections have been only rarely

- 57 reported in humans ¹⁰⁻¹², likely due to the short mean duration of SARS-CoV-2 infections.
- 59

60 Early claims of recombination in SARS-CoV-2¹³ may have been confounded by sequencing

61 errors or convergent evolution ¹⁴. As the COVID-19 pandemic progressed, and genetically

62 divergent lineages have evolved, evidence for recombination between these lineages is

63 becoming more convincing ^{15,16}. Many of these divergent lineages include highly transmissible

64 variants distinguished by S genes that, under positive selection, have accumulated multiple

- 65 mutations associated with increased transmissibility, virulence, and immune escape ^{17,18}.
- 66

Here, we provide a detailed characterization of an instance of superinfection from January 2021,
identified by the New York City (NYC) Department of Health and Mental Hygiene (DOHMH). We
show that this individual was superinfected with two SARS-CoV-2 variants: Alpha (B.1.1.7) and
Epsilon (B.1.429) ^{19,20}. Further, we characterize evidence for recombination occurring within this
superinfected individual, providing an *in vivo* snapshot of this evolutionary process within SARSCoV-2.

73

74 **RESULTS**

75

76 Patient epidemiology. In December 2020, researchers and public health officials in the United 77 Kingdom identified a rapidly spreading SARS-CoV-2 variant within England, then designated as PANGO lineage B.1.1.7²⁰, now designated as the Alpha variant of concern in the WHO 78 nomenclature. In NYC, a SARS-CoV-2 genome sequence classified as belonging to the Alpha 79 80 lineage was obtained from a sample drawn on 4 January 2021 (the 'index case'). Due to the potential public health importance of Alpha variant cases in NYC in early 2021, NYC DOHMH 81 82 conducted a public health investigation related to the individual from which this sample had 83 been obtained: NYCPHL-002130 (GISAID accession number EPI_ISL_857200). This 84 investigation determined that the individual had recently traveled to Ghana (late December/early 85 January), and contact tracing identified another case of an Alpha variant infection, sampled on 86 14 January 2021, in a named contact with a similar travel history (the 'named contact partner'):

87 NYCPHL-002461 (GISAID accession *EPI_ISL_883324*).

89 Atypical Alpha (B.1.1.7) variant PCR screening. Typical of the Alpha variant ²⁰, NYCPHL-

90 002130 exhibited S gene target failure (SGTF) phenotype with the TaqPath COVID-19 RT-PCR

91 assay (Table 1). NYC PHL uses the ARTIC amplicon-based protocol V3 to sequence full viral

92 genomes and capture intrahost diversity. The viral genome from this index case showed limited

93 intrahost viral diversity (Figure 1). A single variable site was found at position 23099, with C in

- 94 20.4% of reads and A in 79.6% of reads. All other substitutions differentiating this sequence
- 95 from the Wuhan-Hu-1 reference genome sequence (*NC_045512.2*) were present in >99.0% of 96 reads.
- 90 97

98 During the initial PCR screening of the sample collected from the named contact partner

99 (NYCPHL-002461), the SGTF characteristic of the Alpha variant was not observed (Table 1).

100 Furthermore, genome sequencing revealed substantial intrahost viral diversity within the viral

- 101 genome, a possible signature of superinfection (Figure 1). To confirm that this intrahost diversity
- 102 was not attributable to experimental or sequencing artifacts, the original sample was re-
- 103 extracted and re-sequenced (NYCPHL-002461-B) and similar SGTF was observed. Additional
- 104 extractions were then performed in duplicate from the original stock (NYCPHL-002461-C and -
- D) and sequenced. The same signature of intrahost diversity was confirmed in all four
- 106 sequenced extractions. Four nucleotide (nt) substitutions differentiating this sequence from the
- 107 reference genome were identified at >90% frequency: C241T, C3037T, C14408T, and
- 108 A23403G. Numerous additional substitutions, including A23063T (S N501Y), were present, but
- 109 at slightly lower frequencies. Nonetheless, this genome was classified as an Alpha variant.
- 110 Notably, the $\Delta 69/70$ and $\Delta 144$ deletions were found at >95% in the sequencing reads, despite 111 the lack of SGTF.
- 112

113 NYCPHL-002461-A, -B, and -D extracts exhibited low Ct values for the ORF1ab and N gene

targets, ranging between 15 and 16 (Table 1). The S gene target Ct values were around 2 to 3

115 cycles higher. The difference suggests a reduction of viral template in the S gene target region,

but not SGTF. We note NYCPHL-002461-C yielded an invalid result, as the TaqPath assay

showed no amplification on all targets, including the MS2 phage extraction-control target.

118

Intrahost diversity. The presence of multiple intermediate frequency alleles and the lack of
 SGTF in the TaqPath assay prompted us to investigate the intrahost diversity in the named
 contact partner, NYCPHL-002461. Major and minor intrahost strains were distinguished using
 the previously described and validated Galaxy SARS-CoV-2 allelic variation pipeline ²¹.

124 The four replicate sequencing runs for NYCPHL-002461 yielded remarkably similar patterns 125 with allelic frequencies segregating into four categories: shared, major strain, minor strain and

126 other (see Figure 1, interactive notebook at https://observablehg.com/@spond/nyc-

- 127 superinfection). Shared alleles were those present at 90% allele frequency (AF) in three or more
- samples. The four shared alleles constituting substitution mutations are the same substitutions
- 129 that define the ancestor of the Lineage B viruses circulating in the United States: C241T,
- 130 C3037T, C14408T, A23403G (Figure 1; Supplementary Table 1). Two deletions in the S gene
- 131 (Δ 69-70 and Δ 144) were also present at high AF (>97%).
- 132

- 133 Major strain alleles are those that occurred at frequencies between 60 and 90% (≥3 samples),
- 134 with all diagnostic Alpha mutations in this set. Minor strain alleles are those that occurred at
- frequencies between 10 and 25% (\geq 3 samples), with all but one diagnostic Epsilon mutation in
- this set; the A28272T mutation characteristic of Epsilon is absent in NYCPHL-002461. Notably,
- 137 the "other" category encompasses all other variable sites, i.e. those occurring at AF between
- 138 25% and 60% or those found in only one or two samples. The two alleles were found in all four
- replicate sequences at intermediate frequencies: G7723A (30.3%) and C23099A (46.7%).
- 140 These frequencies are suggestive of intrahost variation in the major strain.
- 141
- In contrast, the sequencing dataset for the index case, NYCPHL-002130, showed all but one of
 the alleles occurring at ≥85%, and all but one of the alleles (C14676T) were also found as
- 144 "shared" or "major strain" classes in the NYCPHL-002461 datasets (Figure 1). The C23099A
- 145 mutation, which was at intermediate frequency in NYCPHL-002461, was present at only 88.1%
- in NYCPHL-002130 from the index case, suggesting the transmission of a mixed viral
- 147 population between these individuals.
- 148

149 **Phylogenetic inference with major and minor variants.** We identified sub-clades within

- 150 Alpha and Epsilon that shared substitutions with the major and minor strains (Figure 2). We
- 151 inferred a maximum likelihood (ML) phylogenetic tree in IQTree2 for the major strain and 1174
- related B.1.1.7 genomes containing the C2110T, C14120T, C19390T, and T7984C substitutions found in the major strain (Figure 2A). We also inferred an ML tree for the minor strain and 807
- related B.1.429 genomes containing the C8947T, C12100T, and C10641T substitutions found in the minor strain (Figure 2C).
- 156

Root-to-tip regression analyses show that the NYCPHL-002461 sampling date is consistent with
 the molecular clock for both the major and minor strain sequences (Figure 2B/2D), indicating
 that one would expect viruses of this degree of genetic divergence to have been circulating in

- 160 mid-January 2021. In fact, genomes identical to the major variant were sampled in both NYC
- 161 (the NYCPHL-002130 index case) and in Ghana (EPI_ISL_944711) on 8 January 2021,
- 162 consistent with a scenario in which this particular Alpha virus was introduced into NYC by an
- individual who had recently traveled to Ghana and had contact with the named contact partner.
 These three viruses share a common ancestor around 4 January 2021 and are separated by
- additional viruses sampled in Ghana by two mutations: C912T and C23099A. Notably, the latter
- 166 mutation appears at intermediate frequency in both NYCPHL-002130 and NYCPHL-002461.
- 167
- 168 The minor variant is genetically distinct from all other sampled genomes, including any genome
- 169 sequenced by NYC DOHMH (Figure 2C). The closest relatives were sampled in California
- 170 (EPI_ISL_3316023, EPI_ILS_1254173, EPI_ISL_2825578), the United Kingdom
- 171 (EPI_ILS_873881), and Cameroon (EPI_ISL_1790107, EPI_ISL_1790108, EPI_ISL_1790109).
- 172 The most similar of these relatives is EPI_ISL_3316023, which was sampled on 11 January
- 173 2021 in California and represents the direct ancestor of the minor variant on the phylogeny. The
- only mutation separating these genomes is T28272A, which is a reversion away from an
- 175 Epsilon-defining mutation. There are no sequenced closely related Epsilon genomes from NYC,

although this variant was present at a prevalence around 1% in NYC during the first two weeks
 of 2021 in NYC ²².

178

179 Four-gamete tests of recombination. A preliminary inquiry of the genome sequencing data 180 from the S (12 contiguous read fragments) and nucleoprotein (3 contiguous read fragments) 181 regions was suggestive of recombinant genome fragments within the named contact partner. To 182 determine whether pairs of polymorphic sites within individual read fragments displayed 183 evidence of recombination we employed three different four-gamete based recombination detection tests: PHI²³, MCL, and R² vs Dist²⁴ (Table 2). The power of each of these tests to 184 detect recombination was seriously constrained by the short lengths of the read fragments and 185 186 the low numbers of both variant-defining sites and other polymorphic sites with minor allele 187 frequencies >1% within each of the fragments. Only three of the 15 read fragments (read 188 fragments 6 and 8 in the S-gene and read fragment 3 in the N-gene) encompassed two or more 189 of the variant-defining sites that were expected to provide the best opportunities to detect 190 recombination. Nevertheless, pairs of sites within four read fragments in the S gene (positions 191 23123-24467 covering fragments 7, 8, 9 and 10) and one read fragment in the nucleoprotein 192 gene (positions 28986–29378 covering fragment 3) exhibited signals of significant phylogenetic 193 incompatibility with at least two of the three tests (p < 0.05): signals which are consistent with 194 recombination. The only read fragment for which evidence of recombination was supported by 195 all three tests was fragment 3 in the N-gene: a fragment that was one among only three that 196 contained multiple variant-defining sites. Eight of the fifteen analyzed read-fragment alignments 197 exhibited no signals of recombination using any of the tests, which is unsurprising given the lack 198 within these fragments of both variant-defining substitutions and polymorphic sites with minor 199 allele frequencies greater than 1%.

200

Targeted sequencing for recombination detection. The four gamete tests on genomic sequencing data is limited by the short length of amplified fragments. To obtain data from longer sequence fragments, we PCR-amplified three regions of the genome from the original nucleic acid extracts, cloned them, and then sequenced individual clones. These longer genomic fragments provide greater resolution for detecting recombination, compared with the short fragments from deep sequencing analysis, because they include more differentiating sites spread out farther across the genome.

208

209 The longest cloned region spanned 947 nt within the S gene and contained 5 nt substitutions 210 differentiating the major and minor strains plus a variable site in the major variant. Of the 104 211 clones sequenced within this region, 60 (57.7%) were major strain haplotypes, 13 (12.5%) were 212 minor strain haplotypes, whereas the remaining 31 clones (29.8%) contained both major and 213 minor strain mutations, consistent with recombination (Figure 3A). We observed 11 distinct 214 combinations of major and minor strain mutations across these clones, with two distinct 215 haplotypes present in 6 clones apiece. Most haplotypes are consistent with only a single 216 recombination breakpoint, though we did observe clones consistent with 2 or 3 breakpoints. 217 218 The second cloned S region spanned 658 nt in S including the Δ 69-70 and Δ 144 deletions

characteristic of the major strain and two 2 substitutions in the minor strain. Of the 93 clones

sequenced, 69 (74.1%) were major strain haplotypes, 17 (18.3%) were minor strain haplotypes, and 7 (7.5%) were mixed haplotypes (Figure 3B). Five of these mixed haplotypes contained only one of the two deletions. Unlike in the primary sequencing analyses where the Δ69-70 and Δ 144 deletions were present in >98% of sequences, Δ69-70 was observed in only 72 (77.4%) clones and Δ144 was observed in only 71 (76.3%). These frequencies are consistent with the

- frequency of the other major strain substitutions in the primary sequencing analysis.
- 226

The third, and shortest, cloned region spanned 476 nt of ORF8, surrounding 4 substitutions
defining the major strain and 1 minor strain substitution. Of the 36 cloned sequences, 30
(83.3%) had the major strain haplotype, 2 (5.6%) had the minor variant haplotype, and 4
(11.1%) had mixed haplotypes consistent with recombination (Figure 3C). Notable, the

- discriminating substitutions only span 223 nt of this region.
- 232

233 **Consistency between cloning and genome sequencing analyses.** *In-vitro* recombination 234 can be introduced by reverse-transcription and PCR amplification, which are part of both genome sequencing and cloning protocols ²⁵. These *in-vitro* effects have a strong stochastic 235 component and would result in substantially different recombinant haplotype frequencies across 236 237 different extracts and PCR experiments. To determine the extent to which these protocols could 238 have led to biased inference of recombination, we compared the haplotype frequencies across 239 the four extracts from NYCPHL-002461, which had each independently been subjected to 240 reverse transcription and PCR amplification, and the frequency of these haplotypes in the 241 cloning experiment, which included PCR amplification.

242

243 Within the S gene substitution region encompassing nucleotide positions 23604-23709, the 244 major haplotype was present between 76.4% and 78.6%, and the minor haplotype was between 245 13.7% and 15.4% (Supplementary Table 1). The recombinant haplotype positions 23604A and 246 23709C was present at 3.9% allele frequency (standard deviation of 0.34% across extracts), 247 whereas recombinant haplotype 23604C and 23709T was present at 4.3% (standard deviation 248 of 0.37% across extracts). Although the haplotype frequencies among extracts were significantly 249 different (p=0.029; chi-square test), the magnitude of these differences were unremarkable. 250 Furthermore, there was no significant difference between the frequency of these haplotypes in cloning experiment and extracts (p=0.190 versus -A; p=0.189 versus -B; p=0.357 versus -C; 251 252 p=0.206 versus -D; Fisher's Exact Test).

253

A similar pattern was observed within the ORF8 region at nucleotide positions 27972–28111,

which included four discrimination sites: 27972, 28048, 28095, and 28111 (Supplementary
 Table 2). The predominant recombinant haplotypes were consistent across the four extracts,

257 and the frequencies differed only slightly (p=0.077; chi-square test). As in S, the frequency of

these recombinant haplotypes in the cloning experiment was not significantly different from any

of the extracts (p=0.405 versus -A; p=0.413 versus -B; p=0.199 versus -C; p=0.408 versus -D;

260 Fisher's exact test).

Hence, *in-vitro* recombination induced by either reverse-transcription or PCR amplification, does
not appear to have been the dominant contributor to the recombinant haplotype distribution
reported here.

Search for transmission of a circulating recombinant. To determine whether there was onward transmission of a recombinant descendent of these major and minor strains, we queried the 27,806 genomes sequenced by NYC public health surveillance and deposited to GISAID through 05 September 2021. We tested these genomes for mosaicism (3SEQ; ²⁶; with Dunn-Sidak correction for multiple comparisons) of the major and minor strains; however, we were unable to reject the null hypothesis of non-reticulate evolution for any of these genomes. There is no evidence of an Alpha/Epsilon recombinant that circulated in New York City.

273

265

274 Since the Dunn-Sidak correction done in the 3SEQ analysis applies a conservative type-1 error 275 threshold of 0.05, we reran the analysis using a more permissive threshold of 0.25 (see 276 methods) and were able to reject the null hypothesis for a single genome (EPI_ISL_2965250: $p=2.24 \times 10^{-6}$ and Dunn-Sidak corrected p=0.117). Although this genome contains many of the 277 278 mutations characteristic of the Alpha variant throughout the genome, it does not possess 279 mutations unique to the major strain nor any Epsilon-specific mutations. Rather, within the 280 putative recombinant regions, the EPI_ISL_2965250 genome has C8809T, C27925T, C28311T, 281 and T28879G. All of these mutations are characteristic of the B.1.526 lota-variant, prevalent in 282 NYC in early 2021. Therefore, this genome is likely not a descendant of the major and minor 283 strains. Instead it appears to be a recombinant descendant of Alpha and lota viruses.

285 DISCUSSION

286

284

Here, we report evidence of intra-host recombination of SARS-CoV-2 within a single individual
 superinfected with Alpha and Epsilon viral variants during the second COVID-19 wave in New
 York City in early 2021. Because recombinant viruses can be successfully generated and
 transmitted¹⁵ between humans, this finding underscores their potential relevance to the future of
 the COVID-19 pandemic.

292

293 The presence of major and minor strains described within the superinfected individual are 294 unlikely to be the result of bioinformatics error, contamination, or experimental artifacts. The 295 degree of evolutionary divergence of each of the strains from other available SARS-CoV-2 296 genomes is consistent with viruses circulating at the time of their January 2021 sampling dates. 297 Moreover, the major strain genome is identical to contemporaneously sampled genomes from 298 both a named contact and strains circulating in the country from which they had both recently 299 visited. No closely related genome to the minor strain was ever sequenced by NYC DOHMH, 300 lessening the probability of a contaminated sample. Given the relatively low sequencing 301 coverage in NYC in January 2021 and low prevalence of the Epsilon variant, around 1% in NYC 302 at the time, it is not unexpected that a closely related genome would not be observed. 303 Furthermore, the major and minor variants were both present in all four extractions of the two 304 aliquots at similar frequencies, indicating that any contamination, if present, would need to have 305 occurred in the original sample swab.

306

The timing of this superinfection is important, because January 2021 was the peak of the
second COVID-19 wave in NYC, a time when numerous variants were circulating and
immediately prior to the vaccination roll-out campaign. Hence, January 2021 in NYC represents
not only the height of potential for superinfection risk, but also a location where its existence

- 311 would be most apparent due to the co-circulation of numerous genetically distinct viral variants.
- 312

313 There remain unexplained patterns in the genome sequencing data from the superinfected 314 individual. Evidence of a major and minor strain was not apparent at the S deletions $\Delta 69/70$ and 315 Δ 144 in the genome sequencing, but the cloning analysis showed major and minor alleles at 316 these sites at the expected frequencies. Therefore, it is possible that the ARTIC protocol 317 preferentially sequenced templates containing these deletions, giving a false impression of their 318 predominance in the genomic analysis. Also of interest is the A28272T mutation in the minor 319 strain, which is either a reversion or potential sequencing artifact. If the base-call at position 320 28272 in the minor variant is erroneous, then the minor strain would be identical to a virus 321 sampled contemporaneously in California, where the Epsilon variant was first discovered and 322 likely originated.

323

324 Laboratory induced recombination is a common artifact during reverse-transcription and PCR ^{27,28}. However, recombination is a pervasive feature of natural coronavirus infection, as it has 325 been observed in bats, camels, and humans ^{2,15,29,30}. One would a priori expect to find 326 327 recombinant viruses in a SARS-CoV-2 superinfected individual. Therefore, it is unlikely that the 328 entirety of the signal for recombination reported here is due to reverse-transcription or PCR-329 induced recombination. A consistent signal for recombination was observed in the four whole 330 genome sequencing analyses and in cloned-fragment analysis, all suggesting the same 331 recombinant haplotypes present at high frequency.

332

Our search for Alpha/Epsilon variant recombinants in NYC did not identify genomes that would
 suggest onward transmission of either of the major or minor strains derived here, or a
 recombinant offspring. This lack of onward transmission is not surprising, given that the initial
 index case was contacted by NYC DOHMH personnel and their named contact (the
 superinfected case) received a prompt COVID-19 diagnosis and was advised to self-isolate.

338

It is likely that superinfection with SARS-CoV-2 is more common than has been described in the
 literature, especially given the documentation of circulating recombinant strains of the Alpha
 variant in the United Kingdom ¹⁵. Recombinant virus can only be produced within a

- superinfected individual. That said, we caution against assuming superinfection before potential
 issues of contamination, poor-quality sequencing, or bioinformatics errors have been
- 344 appropriately dealt with.345
- The high number and genomic variability recombinant haplotypes that we have identified withina single superinfected individual suggests that recombination is perpetually occurring within
- 348 SARS-CoV-2 infections. Whether recombination will play a role in the emergence of novel
- 349 SARS-CoV-2 variants is an open question. Reduced incidence due to vaccine-induced and

- 350 naturally-acquired immunity would lower the opportunity for superinfection, and the
- 351 homogenizing effect of variant-driven selective sweeps (as seen in the Delta and Omicron
- 352 variants ³¹) will lessen the potential for biological innovation in a recombinant genome.
- 353 Nonetheless, SARS-CoV-2 molecular surveillance should actively monitor for the emergence of
- 354 a recombinant variant.
- 355
- 356

357 MATERIALS AND METHODS

358

359 Extraction and sequencing. Nasopharyngeal specimens positive for SARS-CoV-2 with Ct < 32 360 were submitted to NYC PHL for sequence analysis by the NYC DOHMH through the COVID 361 Express clinics. The NYCPHL-002130 and -002461 specimens had Ct values of 19 and 20 362 cycles, respectively, which allowed for sequencing at NYC PHL. Each specimen was split into 363 separate extraction and archive aliquots. Nucleic acid extraction was performed using the 364 KingFisher Flex Purification System (Thermo Fisher Scientific) from the extraction aliquot. 365 Eleven µL of extract was used to anneal with random hexamers and dNTPs (New England 366 Biolabs Inc., NEB) and reverse transcribed with SuperScript IV Reverse Transcriptase at 42 °C 367 for 50 min. The cDNA product was amplified in two separate multiplex PCRs with ARTIC V3 368 primer pools (Integrated DNA Technologies) in the presence of Q5 2x Hot Start Master Mix 369 (NEB) at 98 °C for 30 s, and 35 cycles of 98 °C for 15 s and 65 °C for 5 min. The two PCR 370 products were combined and were purified with Agencourt Ampure XP magnetic beads 371 (Beckman Coulter) at a 1:1 sample-to-bead ratio. The bead-cleaned PCR products were 372 quantified using a Qubit 3.0 fluorometer (Thermo Fisher Scientific). Standard protocol was used 373 for library preparation in the NEBNext Ultra II Library Preparation workflow using 90 ng of PCR 374 product (NEB). In short, the ARTIC PCR products were used in an end-repair reaction, which 375 added a 5'-phosphate group and a dA-tail, in a reaction for 30 min at 20 °C. The reaction was 376 heat inactivated for 30 min at 65 °C. NEBNext Adaptor was ligated at 25 °C for 30 min and 377 cleaved by USER Enzyme at 37 °C for 15 min. The product was Agencourt Ampure XP bead-378 purified at a ratio of 0.6x sample:beads. The bead-cleaned, end-ligated amplicons were 379 subjected to a 6-cycle PCR reaction with NEBNext Ultra II Q5 Master Mix in the presence of 380 NEBNext Multiplex Oligos for Illumina (NEB), which added a sample-specific 8-base index and 381 Illumina P5 and P7 adapters for sequencing on Illumina instruments. The product was purified 382 with Ampure XP beads at a 0.6x sample:bead ratio and quantified, normalized and pooled at 383 equimolar concentration with other libraries, followed by loading onto the Illumina MiSeq 384 sequencing instrument using V3 600-cycle reagent kit, with a V3 flow cell for 250-cycle paired-385 end sequencing (Illumina). For NYCPHL-002461, the same "extraction" specimen aliguot was 386 used for a second extraction, Extract B. Extracts C and D were independent extractions, but 387 from the "archived" specimen aliquot. As such, the first extract (A), and extracts B, C, and D 388 were independent samples which underwent independent reverse transcription, ARTIC PCR, 389 library preparation, and sequencing reactions.

390

391 Potential in vitro recombination that occurred during the four independent extractions, reverse-392 transcription reactions, and library preparation procedures, such as PCR amplification, would 393 require the events to occur independently at the same stage four times in order to produce the 394 same proportions of Major and Minor variant haplotypes in the high-throughput sequencing 395 data. To account for in vitro recombination, regions where long complete reads span across 396 major and minor variants in close proximity, <105 nucleotide bases, were examined across all 397 genome alignments of the four NYCPHL-002461 replicates. Reads with SAM (Sequence 398 Alignment Map) Flags 81,83,97,113,145,147,161,177,2129 are included in the analysis. Reads 399 with other flags are excluded from the analysis or are not found in the alignment files. 400 Additionally, reads without a combination of major or minor alleles are excluded. All unique

401 haplotypes at major and minor variant positions are grouped together. Relative frequencies of402 the haplotypes are calculated for each region of all four extractions.

- 403
- 404

405 Cloning. Three regions of the SARS-CoV-2 genome from NYCPHL-002461 were cloned. Two
406 contained non-overlapping regions of the S gene and were designated S_Subs (positions
407 22882–23873) and S_Del (positions 21421–22098). The third region included part of the ORF8
408 gene (positions 27798–28280).

- 409
- 410 To perform the annealing step for reverse transcription, 3 µl of the NYCPHL-002461 nucleic
- 411 acid extract was combined with reverse primer and dNTPs at final concentrations of 154 nM and
- 412 769 μ M, respectively. Annealing was performed by heating to 65°C for 5 minutes then cooling to
- 4°C. The reverse primer sequences used for the reverse transcription are as follows: S_Subs
 primer-R is 5□-CTATTCCAGTTAAAGCACGGTTT, S_Del is 5□-
- 414 philler-K is 5 -- CTATTCCAGTTAAGCACGGTTT, S_DEITS 5 --415 AGGTCCATAAGAAAAGGCTGAGA and ORF8 is 5 -- GAGACATTTAGTTTGTTCGTTTA. An
- 416 elongation mix containing 200 units of SuperScript IV Reverse Transcriptase (Invitrogen) and 40
- 417 units of RNaseOUT Recombinant Ribonuclease Inhibitor (Invitrogen) was then added along with
- 418 dNTPs at a final concentration of 200 μ M. The resulting solution was heated to 55°C for 10
- 419 minutes then 80°C for 10 minutes.
- 420 Each cDNA target was PCR amplified using Platinum II Taq polymerase and its accompanying
- 421 buffer (Invitrogen) supplemented with a final concentration of 200 μM dNTPs and 600 nM of
- 422 each primer. The reverse primer sequences used for reverse transcription were included along
- 423 with their corresponding forward primers: S_Subs primer-F is $5\Box$ -
- 424 TCTTGATTCTAAGGTTGGTGGT, S_del is 5□-AGGGGTACTGCTGTTATGTCT and ORF8 is
- 425 5 -GCCTTTCTGCTATTCCTTGT. PCR was performed with the following cycling conditions: an
- 426 initial hold at 94°C for 2 minutes, followed by 35 cycles at 94°C for 15 seconds, 60°C for 15
- 427 seconds and 68° C for 15 seconds. Cycling was followed by a final extension step at 72°C for 7
- minutes. The PCR products were run on 2% agarose gels, excised and gel purified with the
- 429 GenElute Gel Extraction Kit (Sigma). The gel-purified PCR products were cloned using the
- 430 TOPO TA Cloning Kit for Sequencing (Invitrogen).
- 431 Individual colonies resulting from the transformation into chemically competent One Shot
- 432 TOP10 Escherichia coli (Invitrogen) were picked and patch plated for sequencing. Rolling circle
- 433 amplification and Sanger sequencing of the clones were performed by GeneWiz (New Jersey).
- All clones were sequenced with the M13 reverse primer. Due to its larger size, S_Sub clones
- 435 were also sequenced with the M13 forward primer.
- 436 **Major and minor variant calling.** We used the Galaxy SARS-CoV-2 variant calling pipeline for
- 437 paired-end Illumina ARTIC amplicon data ²¹. Briefly, the workflow performs quality control,
- masks primer sites, maps reads to reference using *BMA-mem*, calls variants using *lofreq*,
- annotates them using *SNPEff*, and outputs tabular variant call files, thresholded on minimum
- allele frequency of 0.05. These variants are further visualized in a custom ObservableHQ
 notebook (https://observablehg.com/@spond/nyc-superinfection).
- 442

443 Alignment and phylogenetic inference. SARS-CoV-2 genomes were downloaded from GISAID on 24 March 2021. Genomes assigned to the B.1.1.7 or B.1.429 Pangolin lineage ³² 444 were aligned to the Wuhan-Hu-1 reference genome using the --6merpair option in Mafft v7.464 445 ³³. We further refined these alignments to only those genomes sharing specific synapomorphies 446 447 with the major and minor allelic variants from NYCPHL-002461: C241T, C3037T, C14408T, and 448 A23403G for B.1.1.7 viruses and C8947T, C12110T, and C10641T for B.1.429 viruses. 449 Separate maximum likelihood phylogenetic trees for B.1.1.7 (n=1176) and B.1.429 (n=807) were inferred in IQTree2 under a GTR+F+I model, with the additional NNI search option and a 450 451 minimum branch length of 1e-9 substitutions/site³⁴.

452

453 Molecular clock inference. To determine whether the major and minor allelic variants were
454 contemporaneous with the date of sampling, we estimated clock trees for the B.1.1.7 and
455 B.1.429 phylogenies in TreeTime v0.8.0³⁵. We fixed the clock rate to 8x10⁻⁴
456 substitutions/site/year under a skyline coalescent model (per NextStrain default parameters for
457 SARS-CoV-2). These trees were also used to estimate the time to most recent common

- 457 SARS-Cov-2). These frees were also used to estimate the time to most recent 458 ancestor of the allelic variants and their closest relatives.
- 459

460 Four-gamete tests for recombination. When sequences evolve in the absence of both 461 recombination and convergent mutations it is expected that, for any pair of polymorphic sites 462 where one of the sites has either nucleotide X or Y and the other has either nucleotide A or B, 463 no more than three of the four possible combinations of nucleotides (or gametes) at the two 464 sites (i.e. XA, XB, YA and YB) should ever be observed. Given that in reality convergent 465 mutations are always possible, four gamete tests of recombination attempt to detect situations 466 where the numbers of site pairs where all four combinations of nucleotides are observed exceed 467 that expected due to convergent mutations in the absence of recombination. We tested 15 468 multiple sequence alignments, each containing all observed unique read fragment sequences 469 spanning the S-gene (12 fragments) and N-gene (3 fragments) with three different four gamete tests: (1) the PHI test (implemented in RDP5^{23,36}) which considers sites with more than two 470 471 alternative nucleotide states and uses a permutation-based test to determine whether detected 472 site pairs displaying all four gametes display a degree of spatial clustering along the sequence that is significantly higher than would be expected in the absence of recombination; (2) the MCL 473 474 recombination detection test (implemented in the pairwise component of the LDHat package; ²⁴) 475 which uses an approximate maximum likelihood method to infer the population scaled 476 recombination rate needed to explain the observed numbers of site pairs with four gametes and 477 then tests for significant deviation of the inferred recombination rate from zero using a permutation test, and (3) the RvsDist test (implemented in pairwise component of LDHat) which 478 determines the correlation between the R² measure of linkage disequilibrium between site pairs 479 with four gametes with the physical distance in nucleotides between the site pairs ²⁴ and uses a 480 481 permutation test to detect significant deviations from the expected degree of correlation in the 482 absence of recombination. For both the MCL and RvsDist tests we used a minor allele 483 frequency cutoff of 0.01.

484

485 **Population level recombination detection.** We downloaded all SARS-CoV-2 sequences from
 486 GISAID that were deposited by 5 September 2021 ³⁷ and analyzed the 27,806 genomes

487 sequenced by the NYC PHL and Pandemic Response Lab (PRL) from specimens collected
488 from NYC residents. These genomes were aligned to the Wuhan-Hu-1 reference genome

489 (Genbank accession NC_045512.2) using MAFFT v7.453 (options --auto --keeplength --

490 addfragments) ³³.

491

To determine whether there was any onward transmission of a major-minor strain recombinant,
 we used 3SEQ v.1.7 ²⁶ as a statistical test for recombination in the NYC data. 3SEQ

494 interrogates triplets of sequences for signals of mosaicism in a sequence given two 'parental'

495 sequences. We interrogated each of the 27,806 NYC PHL and PRL-generated genomes for

- 496 mosaicism given the major and minor strains as parents. The resulting *p*-values are Dunn-Sidak
- 497 corrected for multiple comparisons (n=55612), and we tested for mosaicism at *p*-value
- thresholds 0.05 and 0.25. The single nucleotide differences between a putative recombinant
- 499 and the major and minor strains were visualized using snipit
- 500 (https://github.com/aineniamh/snipit).

501

503 Data availability.

- 504 The data analyzed as part of this project were obtained from the GISAID database and through
- a Data Use Agreement between NYC DOHMH and the University of California San Diego. We
- 506 gratefully acknowledge the authors from the originating laboratories and the submitting
- 507 laboratories, who generated and shared via GISAID the viral genomic sequence data on which
- this research is based. A complete list acknowledging the authors who submitted the data
- analyzed in this study can be found in Data S1.
- 510
- 511 Trimmed, host-depleted viral sequencing data and cloned sequence fragments have been
- 512 submitted to NCBI (accession numbers pending).
- 513

514 Acknowledgements.

- 515 J.O.W. acknowledges funding from the National Institutes of Health (AI135992 and AI136056).
- 516 D.P.M was funded by the Wellcome Trust (222574/Z/21/Z). PKQ is funded by a Crick African
- 517 Network Fellowship. T.I.V. is funded by a Branco Weiss Fellowship. S.L.K.P and A.N were
- 518 supported in part by a grant from the National Institutes of Health (AI134384). This work was
- supported (in part) by the Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases
- 520 Cooperative Agreement (Grant Number: ELC DETECT (6NU50CK000517-01-07) funded by the
- 521 Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of
- 522 the authors and do not necessarily represent the official views of CDC or the Department of
- 523 Health and Human Services.
- 524

525 **Competing interests.**

- 526 J.O.W. and S.L.K.P has received funding from the CDC (ongoing) via contracts or agreements
- 527 to their institution unrelated to this research. All other authors declare no competing interests.

528		
529	REFE	ERENCES
530		
531	1	Worobey, M. & Holmes, E. C. Evolutionary aspects of recombination in RNA viruses. J
532	•	Gen Virol 80 (Pt 10) , 2535-2543 (1999).
533	2	Boni, M. F. <i>et al.</i> Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage
534	0	responsible for the COVID-19 pandemic. <i>Nat Microbiol</i> 5 , 1408-1417 (2020).
535	3	Liao, C. L. & Lai, M. M. RNA recombination in a coronavirus: recombination between
536 537	4	viral genomic RNA and transfected RNA fragments. <i>J Virol</i> 66 , 6117-6124 (1992).
537 538	4	Lytras, S. <i>et al.</i> Exploring the natural origins of SARS-CoV-2 in the light of recombination. <i>bioRxiv</i> 2021.01.22.427830 (2021).
539	5	Sabir, J. S. <i>et al.</i> Co-circulation of three camel coronavirus species and recombination of
539 540	5	MERS-CoVs in Saudi Arabia. Science 351 , 81-84 (2016).
541	6	Siapco, B. J., Kaplan, B. J., Bernstein, G. S. & Moyer, D. L. Cytodiagnosis of Candida
542	0	organisms in cervical smears. Acta Cytol 30 , 477-480 (1986).
543	7	Smith, D. M., Richman, D. D. & Little, S. J. HIV superinfection. <i>J Infect Dis</i> 192 , 438-444
544	•	(2005).
545	8	Myers, C. A. <i>et al.</i> Dual infection of novel influenza viruses A/H1N1 and A/H3N2 in a
546		cluster of Cambodian patients. Am J Trop Med Hyg 85, 961-963 (2011).
547	9	Rith, S. et al. Natural co-infection of influenza A/H3N2 and A/H1N1pdm09 viruses
548		resulting in a reassortant A/H3N2 virus. J Clin Virol 73, 108-111 (2015).
549	10	Samoilov, A. E. et al. Case report: change of dominant strain during dual SARS-CoV-2
550		infection. <i>BMC Infect Dis</i> 21 , 959 (2021).
551	11	Tarhini, H. et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
552		CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged
553		Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis 223, 1522-1527 (2021).
554	12	Sjaarda, C. P. et al. Phylogenomics reveals viral sources, transmission, and potential
555		superinfection in early-stage COVID-19 patients in Ontario, Canada. Sci Rep 11, 3697
556	40	(2021).
557 550	13	Yi, H. 2019 Novel Coronavirus Is Undergoing Active Recombination. <i>Clin Infect Dis</i> 71 ,
558 559	14	884-887 (2020). Wertheim, J. O. A Glimpse Into the Origins of Genetic Diversity in the Severe Acute
559 560	14	Respiratory Syndrome Coronavirus 2. <i>Clin Infect Dis</i> 71 , 721-722 (2020).
561	15	Jackson, B. <i>et al.</i> Generation and transmission of interlineage recombinants in the
562	10	SARS-CoV-2 pandemic. <i>Cell</i> 184 , 5179-5188 e5178 (2021).
563	16	VanInsberghe, D., Neish, A. S., Lowen, A. C. & Koelle, K. Recombinant SARS-CoV-2
564	10	genomes are currently circulating at low levels. <i>bioRxiv</i> (2021).
565	17	Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of
566		concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 27, 1379-1384 (2021).
567	18	Martin, D. P. et al. The emergence and ongoing convergent evolution of the SARS-CoV-
568		2 N501Y lineages. Cell 184, 5189-5200 e5187 (2021).
569	19	Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-
570		2 variant. Cell 184 , 3426-3437 e3428 (2021).
571	20	Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
572		Nature 593 , 266-269 (2021).
573	21	Maier, W. et al. Ready-to-use public infrastructure for global SARS-CoV-2 monitoring.
574		Nat Biotechnol 39 , 1178-1179 (2021).
575	22	West, A. P., Jr. <i>et al.</i> Detection and characterization of the SARS-CoV-2 lineage B.1.526
576	00	in New York. <i>Nat Commun</i> 12 , 4886 (2021).
577 570	23	Bruen, T. C., Philippe, H. & Bryant, D. A simple and robust statistical test for detecting
578		the presence of recombination. Genetics 172 , 2665-2681 (2006).

- 579 24 McVean, G., Awadalla, P. & Fearnhead, P. A coalescent-based method for detecting 580 and estimating recombination from gene sequences. *Genetics* **160**, 1231-1241 (2002).
- 581 25 Gorzer, I., Guelly, C., Trajanoski, S. & Puchhammer-Stockl, E. The impact of PCR-582 generated recombination on diversity estimation of mixed viral populations by deep 583 sequencing. *J Virol Methods* **169**, 248-252 (2010).
- Lam, H. M., Ratmann, O. & Boni, M. F. Improved Algorithmic Complexity for the 3SEQ Recombination Detection Algorithm. *Mol Biol Evol* **35**, 247-251 (2018).
- Lenz, T. L. & Becker, S. Simple approach to reduce PCR artefact formation leads to
 reliable genotyping of MHC and other highly polymorphic loci--implications for
 evolutionary analysis. *Gene* 427, 117-123 (2008).
- Schlub, T. E., Smyth, R. P., Grimm, A. J., Mak, J. & Davenport, M. P. Accurately
 measuring recombination between closely related HIV-1 genomes. *PLoS Comput Biol* 6, e1000766 (2010).
- 592 29 Dudas, G., Carvalho, L. M., Rambaut, A. & Bedford, T. MERS-CoV spillover at the camel-human interface. *Elife* **7** (2018).
- Vijgen, L. *et al.* Complete genomic sequence of human coronavirus OC43: molecular
 clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J
 Virol **79**, 1595-1604 (2005).
- 597 31 MIcochova, P. *et al.* SARS-CoV-2 B.1.617.2 Delta variant replication and immune 598 evasion. *Nature* **599**, 114-119 (2021).
- 599 32 O'Toole, A. *et al.* Assignment of epidemiological lineages in an emerging pandemic 600 using the pangolin tool. *Virus Evol* **7**, veab064 (2021).
- Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:
 improvements in performance and usability. *Mol Biol Evol* **30**, 772-780 (2013).
- 60334Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic604Inference in the Genomic Era. Mol Biol Evol 37, 1530-1534 (2020).
- 605 35 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic 606 analysis. *Virus Evol* **4**, vex042 (2018).
- 60736Martin, D. P. *et al.* RDP5: a computer program for analyzing recombination in, and608removing signals of recombination from, nucleotide sequence datasets. Virus Evol 7,609veaa087 (2021).
- 610 37 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data from 611 vision to reality. *Euro Surveill* **22** (2017).
- 612

613 Table 1. Cycle threshold (Ct) values from TaqPath assays from index case (NYCPHL-

002130) and named contact partner (NYCPHL-002461).

Case	WGS ID	Ct value			
Case	W651D	ORF1ab	N gene	S gene	
Index case	NYCPHL-002130	14.97	15.44	N/A	
Named contact partner	NYCPHL-002461-A	14.86	15.70	17.34	
	NYCPHL-002461-B	16.06	16.251	18.68	
	NYCPHL-002461-C	N/A	N/A	N/A	
	NYCPHL-002461-D	15.73	15.83	18.35	

Table 2: Four gamete recombination test results for 15 sets of aligned read fragments in the S (spike) and N (nucleoprotein) genes.

		• 1	- 1	Recombination test <i>p</i> -value			
Gene	Fragment	Start ¹	End ¹	PHI	MCL	R ² vs Dist	
S	1	21354	21730	>0.9	>0.9	>0.9	
	2	21658	22038	>0.9	>0.9	>0.9	
	3	21962	22346	>0.9	>0.9	>0.9	
	4	22263	22650	0.682	0.393	0.132	
	5	22517	22903	>0.9	0.401	0.142	
	6	22798	23212	<0.001	0.355	0.3	
	7	23123	23522	>0.9	<0.001	0.005	
	8	23444	23847	<0.001	0.317	0.008	
	9	23790	24169	>0.9	0.047	0.03	
	10	24079	24467	>0.9	0.003	<0.001	
	11	24392	24789	<0.001	0.071	0.477	
	12	24697	25076	0.741	0.155	0.208	
N	1	28395	28779	0.491	0.482	0.459	
	2	28678	29063	>0.9	0.868	0.628	
	3	28986	29378	<0.001	<0.001	<0.001	

620

¹Position relative to the Wuhan-Hu-1 reference strain



623



Figure 1. The distribution of allelic frequencies in the index case (NYCPHL-002130) and
 named partner with suspected superinfection (NYCPHL-002461). Frequencies of individual
 alleles shown as ticks, a smoothed kernel density plot is used to highlight clustering patterns,
 and colors represent allele types.





Figure 2. Phylogenetic consistency of major and minor variants. (A) Phylogeny of B.1.1.7

632 immediate relatives, (B) Root-to-tip regression for B.1.1.7, (C) Phylogeny of B.1.429 immediate

633 relatives, (D) Root-to-tip regression for B.1.429. NY-NYCPHL-0024661 is the genome deposited

634 in GISAID from the case of putative superinfection.



635

Figure 3. Major, minor, and mixed alleles in cloned sequences. Clones in S-substitution (S_Subs), S-Deletion (S_Del), and ORF8 were sequenced. Major and Minor allele positions are defined by the variant calling analysis performed on Galaxy. For each of the cloned region here, there are clones with only major alleles, minor alleles, and mix of both alleles. Out of the three cloned regions, the S-substitution clones has the highest frequency of mixed variants.



- 641 Figure 4. The nucleotide variation present in the major, minor, and putative recombinant
- 643 strains. The distribution of the nucleotide variation found in the major, minor, B.1.526
- 644 (EPI_ISL_1635735), and single putative recombinant (EPI_ISL_2965250) strains relative to the
- reference genome (Wuhan Hu-1; bottom grey sequence).
- 646
- 647

648 SUPPLEMENTAL TABLES

649

650 Supplementary Table 1. Recombinant haplotype frequencies across separate extractions,

651 reverse transcription, and PCR amplification in high-throughput sequencing for S-

652 Substitution (S_Sub) region, nucleotide positions 23604 and 23709.

653

	Haploty	oes	Count (Frequencies)				
Туре	23604	23709	NYCPHL- 002461-A	NYCPHL- 002461-B	NYCPHL- 002461-C	NYCPHL- 002461-D	
MAJOR	Α	т	3633 (78.57%)	4095 (76.43%)	3778 (76.40%)	4745 (78.24%)	
MINOR	С	С	634 (13.71%)	776 (14.48%)	762 (15.41%)	851 (14.03%)	
МІХ	Α	С	162 (3.50%)	234 (4.37%)	191 (3.86%)	237 (3.91%)	
МІХ	С	т	195 (4.22%)	253 (4.72%)	214 (4.33%)	232 (3.83%)	
Depth			4624 (100%)	5358 (100%)	4945 (100%)	6065 (100%)	

654

655

657 Supplementary Table 2. Recombinant haplotype frequencies across separate extractions,

658 reverse transcription, and PCR amplification in high-throughput sequencing for ORF8

659 region, nucleotide positions 27972, 28048, 28095, 28111.

Positions					Count (Frequencies)			
Haplotype	27972	28048	28095	28111	NYCPHL- 002461-A	NYCPHL- 002461-B	NYCPHL- 002461-C	NYCPHL- 002461-D
MAJOR	т	т	т	G	1382 (70.22%)	1164 (69.83%)	1110 (68.90%)	1873 (70.26%)
MINOR	С	G	Α	Α	381 (19.36%)	305 (18.30%)	347 (21.54%)	505 (18.94%)
МІХ	т	G	Α	Α	57 (2.90%)	40 (2.40%)	31 (1.92%)	77 (2.89%)
міх	С	т	т	G	50 (2.54%)	60 (3.60%)	55 (3.41%)	66 (2.48%)
міх	т	т	Α	Α	40 (2.03%)	43 (2.58%)	28 (1.74%)	48 (1.80%)
міх	С	G	т	G	34 (1.73%)	28 (1.68%)	18 (1.12%)	45 (1.69%)
міх	т	т	т	Α	8 (0.41%)	7 (0.42%)	6 (0.37%)	12 (0.45%)
міх	С	G	Α	G	4 (0.20%)	6 (0.36%)	4 (0.25%)	12 (0.45%)
міх	т	G	т	G	6 (0.30%)	8 (0.48%)	7 (0.43%)	15 (0.56%)
міх	С	т	Α	Α	1 (0.05%)	3 (0.18%)	3 (0.19%)	5 (0.19%)
міх	С	G	т	Α	1 (0.05%)	1 (0.06%)	NULL	NULL
міх	т	т	Α	G	1 (0.05%)	1 (0.06%)	2 (0.12%)	7 (0.26%)
міх	С	т	Α	G	1 (0.05%)	1 (0.06%)	NULL	NULL
міх	т	G	т	Α	1 (0.05%)	NULL	NULL	NULL
міх	С	т	т	Α	1 (0.05%)	NULL	NULL	1 (0.04%)
Depth					1968 (100%)	1667 (100%)	1611 (100%)	2666 (100%)

660

661

662